BTIG raised the firm’s price target on Establishment Labs to $65 from $62 and keeps a Buy rating on the shares as part of a broader research note previewing Q3 results in MedTech. The sector had “solid returns” as Providers outperformed among healthcare sub-sectors at 10.5% for iShares U.S. Healthcare Providers ETF (IHF), and these results track largely in line with fundamental feedback during Q3 as procedure volumes have been healthy and demand is strong, the analyst tells investors in a research note. Channel checks in many sub-sectors also point to sustained procedure demand continuing into 2025 as demographics and low unemployment provide support, the firm added.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ESTA:
- Establishment Labs jumps after first patients receive Motiva breast implants
- Establishment Labs: 1st US women successfully receive BA with Motiva implants
- Establishment Labs price target raised to $50 from $45 at Citi
- Costco reports Q4 earnings beat, Cassava to settle SEC charges: Morning Buzz
- Morning Movers: Bristol Myers jumps after FDA approves schizophrenia treatment